Since 2019, the cost of typical starter homes in the U.S. has risen from $256,000 to $344,000, while affordable listings under $350,000 have dropped from 55% to 37.6%. Higher mortgage rates and limited inventory have pushed the income needed to qualify for a mortgage from $43,000 to $78,000, making it harder for lower-income buyers. The average age of first-time homebuyers has increased to 40 years, with many pooling resources or moving to more affordable areas. New home construction, especially in the South, has added supply and slightly improved affordability, but regional disparities remain significant, with the Northeast facing the toughest conditions.
Axsome Therapeutics received an "Outperform" rating from BMO Capital due to significant progress in its drug pipeline, including FDA acceptance of its NDA for AXS-12, a narcolepsy treatment with a PDUFA date set for May 1, 2027. The company is also a...
Novartis is set to report its Q2 earnings with analysts expecting an EPS of $2.17 and revenue of $14.07 billion, following a tough Q1 affected by major patent expirations. Despite revenue challenges, the company maintained strong cash flow of $3.30 b...
KeyCorp is set to report earnings with analysts forecasting a 20% increase in earnings per share to $0.42 and an 8% rise in total revenue to $1.97 billion. The growth is mainly driven by a 10% increase in net interest income, fueled by strong commerc...
Several biotech and manufacturing companies saw significant stock declines due to key corporate events. Vision Marine Technologies dropped nearly 24% after shifting its focus from boat manufacturing to a mining project, causing investor uncertainty. ...
Shares of Zhengye Biotechnology surged over 1047% to regain Nasdaq compliance after a minimum bid price warning. Advanced Biomed and Axe Compute also saw notable gains following a reverse stock split and Russell Microcap Index inclusion, respectively...
